Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Bristol-Meyers Squibb
Bristol-Meyers Squibb
Industry-wide accelerated approval review yields four withdrawals
RAPS.org
Wed, 03/10/21 - 10:53 pm
FDA
Bristol-Meyers Squibb
Roche
Merck
AstraZeneca
accelerated approvals
Esmo 2020 preview – late-breaking immunotherapy
EP Vantage
Mon, 09/14/20 - 10:53 am
ESMO
immunotherapy
Big Pharma
Merck
Bristol-Meyers Squibb
cancer
Immunomedics
Roche
Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases
Xconomy
Mon, 07/6/20 - 10:48 am
Bristol-Meyers Squibb
Dragonfly Therapeutics
multiple sclerosis
MS
neuroinflammation
I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study
Fierce Pharma
Thu, 06/25/20 - 08:36 pm
immuno-oncology
checkpoint inhibitors
Merck
Bristol-Meyers Squibb
COVID-19
Keytruda
Opidvo
Yervoy
Genentech
Tecentriq
AstraZeneca
Imfinzi
FDA accepts for priority review Bristol Myers Squibb’s application for CC-486 for maintenance treatment of adults in remission with AML
Pharmaceutical Business Review
Mon, 05/4/20 - 10:36 am
Bristol-Meyers Squibb
FDA
CC-486
AML
acute myeloid leukemia
Motion denied: Gilead still on the hook for $1.5B in damages over CAR-T patent dispute with Bristol Myers Squibb
Endpoints
Wed, 04/1/20 - 09:33 am
Gilead Sciences
CAR-T
Bristol-Meyers Squibb
Juno Therapeutics
patents
Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T
Endpoints
Tue, 03/31/20 - 10:47 am
Bristol-Meyers Squibb
CAR-T
Celgene
ide-cel
Bluebird Bio
liso-cel
ozanimod
FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch
Xconomy
Thu, 03/26/20 - 10:42 am
Bristol-Meyers Squibb
Celgene
M&A
ozanimod
MS
mutliple sclerosis
drug launches
FDA
COVID-19
Zeposia